Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by kristian7on Dec 21, 2016 2:23pm
429 Views
Post# 25631065

SAME EXACT SCAM !!! UNREAL !!!

SAME EXACT SCAM !!! UNREAL !!! October 2015 . Nobilis ( NHC.TO ) . The lawsuit follows on the heels of an anonymous post to the website Seeking Alpha by an anonymous poster nicknamed “The Emperor Has No Clothes”. It prompted a sharp selloff in shares of Nobilis that caused the stock to be halted. The post called the company “significantly overvalued” and said insiders have cashed out more than $70-million through a combination of share sales and compensation. The post also said turnover at the CFO level was a “red flag”.The company claims the aforementioned perpetrated a scheme to damage Nobilis’s reputation and business relationships in order to profit through short-selling of Nobilis stock, and the company is seeking $300-million in damages, an amount the company says is approximately equal to its lost market capitalization.
Bullboard Posts